Lyman GH - Search Results

1

Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M; National Comprehensive Cancer Network. Crawford J, et al. Among authors: lyman gh. J Natl Compr Canc Netw. 2011 Aug 1;9(8):914-32. doi: 10.6004/jnccn.2011.0075. J Natl Compr Canc Netw. 2011. PMID: 21900221 No abstract available.

2

Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, et al. Crawford J, et al. N Engl J Med. 1991 Jul 18;325(3):164-70. doi: 10.1056/NEJM199107183250305. N Engl J Med. 1991. PMID: 1711156 Free article. Clinical Trial.

3

Hematopoietic growth factors in the older cancer patient.

Balducci L, Hardy CL, Lyman GH. Balducci L, et al. Among authors: lyman gh. Curr Opin Hematol. 2001 May;8(3):170-87. doi: 10.1097/00062752-200105000-00008. Curr Opin Hematol. 2001. PMID: 11303151 Review.

4

Cost effectiveness of myeloid growth factors in cancer chemotherapy.

Lyman GH, Kuderer NM. Lyman GH, et al. Curr Hematol Rep. 2003 Nov;2(6):471-9. Curr Hematol Rep. 2003. PMID: 14561391 Review.

5

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

Crawford J, Dale DC, Lyman GH. Crawford J, et al. Among authors: lyman gh. Cancer. 2004 Jan 15;100(2):228-37. doi: 10.1002/cncr.11882. Cancer. 2004. PMID: 14716755 Free article. Review.

6

Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.

Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M; OPPS Working Group; ANC Study Group. Lyman GH, et al. Leuk Lymphoma. 2003 Dec;44(12):2069-76. doi: 10.1080/1042819031000119262. Leuk Lymphoma. 2003. PMID: 14959849

7

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Lyman GH, et al. J Clin Oncol. 2004 Nov 1;22(21):4302-11. doi: 10.1200/JCO.2004.03.213. Epub 2004 Sep 20. J Clin Oncol. 2004. PMID: 15381684

8

Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.

Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH. Cosler LE, et al. Among authors: lyman gh. Value Health. 2005 Jan-Feb;8(1):47-52. doi: 10.1111/j.1524-4733.2005.03099.x. Value Health. 2005. PMID: 15841893 Free article.

9

Myeloid growth factors clinical practice guidelines in oncology.

Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, Lyman GH, Michaud L, Motl S, Vadhan-Raj S, Wong MK; National Comprehensive Cancer Network. Crawford J, et al. Among authors: lyman gh. J Natl Compr Canc Netw. 2005 Jul;3(4):540-55. doi: 10.6004/jnccn.2005.0030. J Natl Compr Canc Netw. 2005. PMID: 16038645 No abstract available.

10

Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.

Lyman GH. Lyman GH. J Natl Compr Canc Netw. 2005 Jul;3(4):557-71. doi: 10.6004/jnccn.2005.0031. J Natl Compr Canc Netw. 2005. PMID: 16038646 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

570 results

Search Page